Zonisamide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epilepsy; Paediatric Partial Onset Seizures
Conditions
Epilepsy; Paediatric Partial Onset Seizures
Trial Timeline
Dec 1, 2008 → Mar 1, 2011
NCT ID
NCT00566254About Zonisamide + Placebo
Zonisamide + Placebo is a phase 3 stage product being developed by Eisai for Epilepsy; Paediatric Partial Onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00566254. Target conditions include Epilepsy; Paediatric Partial Onset Seizures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01765608 | Phase 2 | Completed |
| NCT00566254 | Phase 3 | Completed |
| NCT00692003 | Phase 3 | Terminated |
| NCT00693017 | Phase 3 | Terminated |
| NCT00327717 | Phase 3 | Completed |
Competing Products
20 competing products in Epilepsy; Paediatric Partial Onset Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 52 |
| Lacosamide | UCB | Phase 3 | 74 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Zonegran | Eisai | Approved | 85 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| perampanel | Eisai | Approved | 85 |
| E2007 + Placebo | Eisai | Phase 2 | 52 |
| Placebo + Rufinamide | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 52 |
| Perampanel Oral Tablet | Eisai | Approved | 85 |
| perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Approved | 85 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| Perampanel | Eisai | Phase 2 | 52 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 85 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 52 |
| Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/day | Eisai | Approved | 85 |